Stocks
Eli Lilly and Company (LLY) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 413.4% | 299.9% | 375.1% | 289.5% | 126.0% | 131.8% | |||
| Changes by years, y/y, % | +246pp | -113pp | +75pp | -86pp | -163pp | -5.5% | |||
Eli Lilly and Company. R&D/CAPEX, %
Eli Lilly and Company. R&D/CAPEX, changes, pp
Eli Lilly and Company (LLY) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D/CAPEX, % | 219.7% | 281.8% | 60.2% | 155.2% | 255.8% | 131.8% | ||
| Changes by years, y/y, % | +32pp | -113pp | -230pp | -204pp | +36pp | |||
| Changes by quarters, q/q, % | -140pp | +62pp | -222pp | +95pp | +101pp | |||
